Merck & Co Inc
We just got reasons to love these 2 portfolio stocks even more
Investors have a couple of new reasons to like portfolio stocks Broadcom and Goldman Sachs . Deal king: Coterra named Goldman Sachs as a financial advisor on its $58 billion all-stock merger with fellow shale producer Devon . The deal is the largest in the energy sector since Diamondback ‘s $26 billion acquisition of Endeavor […]
Read More
The metal sell-off, Disney earnings, the ‘Melania’ movie and more in Morning Squawk
This is CNBC’s Morning Squawk newsletter. Subscribe here to receive future editions in your inbox. Good morning. America’s favorite groundhog, Punxsutawney Phil, saw his shadow this morning, meaning we’re in for six more weeks of winter. After the recent string of cold temperatures, I can’t say I’m surprised. Stock futures are sliding this morning. The three major […]
Read More
Cramer’s week ahead: Earnings from Eli Lilly, Alphabet and Amazon. Plus, jobs data
The stock market is well-positioned to bounce next week if the heavyweight companies set to report earnings deliver strong numbers, CNBC’s Jim Cramer said Friday. That’s because the market ended the week on a subdued note, the “Mad Money” host said, after the S&P 500 finished in the red for three straight days. The busy […]
Read More
Stocks making the biggest moves midday: GameStop, Booz Allen, CVR Energy, CoreWeave & more
Check out some of the companies making the biggest midday moves: Booz Allen Hamilton — The consulting firm shed more than 5% after the Treasury Department said it canceled all contracts with the company , whose employees leaked the tax records of President Donald Trump, and the billionaires Jeff Bezos and Elon Musk, to media […]
Read More
Drug pricing, patent losses and deals: Here’s what pharma execs see ahead in the industry
US President Donald Trump arrives for an announcement in the Roosevelt Room of the White House in Washington, DC, US, on Friday, Dec. 19, 2025. Will Oliver | Bloomberg | Getty Images Drug pricing. Looming patent cliffs. Dealmaking. The first year of Trump 2.0. Those are among the themes that dominated conversations last week as drugmakers […]
Read More
Healthy Returns: Novo Nordisk CEO on GLP-1 pricing, and more insights from the JPM conference
A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Good morning from San Francisco! It’s day three of the annual JPMorgan Healthcare Conference – the biggest gathering of biotech and pharma execs, investors and analysts in […]
Read More
Healthy Returns: What to expect from pharma at the JPM conference
Heidi Overton, Novo Nordisk CEO Maziar Mike Doustdar, Eli Lilly CEO David A. Ricks, and U.S. Secretary of Commerce Howard Lutnick listen while U.S. President Donald Trump announces a deal with Eli Lilly and Novo Nordisk on to reduce the prices of GLP-1 weight‑loss drugs during an event in the Oval Office at the White […]
Read More
A little-known biotech stock has become a prime takeover target after surging nearly 1,700% last year
Europe’s best-performing blue-chip stock in 2025 is widely expected to be bought by a larger peer, in a deal analysts say could be worth as much as $23 billion. Abivax, the French clinical-stage biotech company developing a treatment for ulcerative colitis and Crohn’s disease, saw shares rocket 1,681% last year, far outpacing the Stoxx 600 […]
Read More
Big Pharma race to snap up biotech assets as $170 billion patent cliff looms
Two employees in pharmaceutical industry wearing protective gloves, mask, cap and white suit seen standing by the machine that is the part of the medicaments production during the working hours in a pharmaceutical manufacturing. Extreme-photographer | E+ | Getty Images A multitude of factors are coming together to bring a big burst in biotech M&A. […]
Read More
These are the most overbought S&P 500 stocks as 2026 approaches
Investors piled into Merck & Co. and S & P Global , among others, with 2026 around the corner. Those names may be due for a pullback. The three major averages all climbed this week, which was shortened because of the Christmas holiday. The S & P 500 led the way with a 1.4% gain. […]
Read More